Home > Quotes > RYTM

Rhythm Pharmaceuticals, Inc. Common Stock Quote & Summary Data

Get RYTM Alerts
*Delayed - data as of Dec. 11, 2017 10:49 ET  -  Find a broker to begin trading RYTM now
Industry: Health Care
Community Rating:
View:    RYTM Real Time
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
Basic Chart Interactive Chart
Company Headlines Press Releases Market Stream
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Intraday Chart

Shares Traded

Trading Range

The current last sale of $28.52 is 33.43% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 29.15 $ 33.81
 Low: $ 28.43 $ 21.375

Company Description (as filed with the SEC)

We are a biopharmaceutical company focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. Our lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity. We believe setmelanotide, for which we have exclusive worldwide rights, has the potential to serve as replacement therapy for the treatment of melanocortin-4, or MC4, pathway deficiencies. MC4 pathway deficiencies result in the disruption of satiety signals and energy homeostasis in the body, which, in turn, leads to intense feelings of hunger and to obesity.  ... More ...  

Risk Grade

Where does RYTM fit in the risk graph?

Risk Grade Scale

Nasdaq Official Price

Consensus Recommendation

Analyst Info